RANI: Impressive Bioavailability for RT-116

By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On February 5th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of semaglutide using the RaniPill High Capacity (HC) device compared to subcutaneous (SC) injection. The study was conducted in eight canines to generate pharmacokinetic (PK) and pharmacodynamic (PD) data evaluating oral...